Back to "Uncontrolled Spread" authored by the gifted Scott Gottlieb.
Chapter 17 continued.
In this chapter he patiently, in excruciatingly painful detail, describes the manufacturing process of developing vaccines.
This has left me head scratching.
When manufacturing traditional vaccines, the original virus sample is required, then it has to be grown in large vats and then deactivated. Next up,
large manufacturing facilities are required for mass production.
While we were forced to be the mRNA clinical trial participants China kept with the traditional approach.
Key point- How was China, using the traditional process, able to mass produce a vaccine for a very large population? This would require enormous
facilities and could very well take more than a year to successfully manufacture.
Not in the book - They would need eggs, millions of them, at the same time they were experiencing a deadly outbreak of Avian flu in chickens.
Then to double down, what about the mutations? More eggs. More of everything.
This explains why the mRNA approach was taken. Millions of eggs were not required and plug-and-play comes to mind.
Clinical Trials:
Page 329. Something for us to consider. Pfizer and BioNTech started working together on an influenza vaccine in 2018 thanks to Billy the Gates.
They were set to start clinical trials early 2020.
That would mean that they had testing partners and clinical trial sites already selected. Rather handy.
Keeping track of resignations- Kathryn Janson.
Kathryn Janson
A key player who green lit the mRNA approach. The mindset-
"And now we are building the infrastructure for mRNA vaccine dealing with this pandemic, and of course this builds a foundation to deal with
everything else in the future." Covid would provide a large-scale vaidation for this approach.
Make of this what you will-
July 24, 2020 they selected the full length spike protein which meant [at least to them] "No single mutation would render the vaccine substantially
less effective." So why the boosters???
July 27, 2020 [17] Pfizer and Moderna both started phase 3 [pivotal] trials.
"For the first time we had the ability to develop fully synthetic vaccines based on information about a pathogen's genetic sequence."
We need to let this sink in a bit.
Albert Bourla made some very unusual decisions. Traditional vaccine manufacturing is very sequential but he chose to proceed in parallel.
While testing the different candidates Pfizer proceeded building custom- made systems to manufacture vaccines in large quantities at a cost of $2
billion.
Imagine
a novel manufacturing facility and novel equipment all for a novel vaccine for a novel virus.
This was done long before Pfizer knew that the jabs might be effective.
Meanwhile accepting no $ from the federal government?
Now that's what I call confidence.